Skip to main content
. 2017 Aug 8;9(11):9608–9617. doi: 10.18632/oncotarget.20033

Figure 3. SMARCA4 re-expression in SMARCA4-deficient pancreatic cancer cells reduces sensitivity to DNA-damaging agents.

Figure 3

(A) SMARCA4 re-expression in SMARCA4-defieicint PANC1 cells confirmed by western blot, compared to empty vector control; GAPDH serves as a loading control. (B) Bar graph summarizing fold-increases in IC50 with SMARCA4 (vs. empty vector) re-expression, in PANC1 and Hs700T cells, for 6 different chemotherapy agents. (C–H) Dose-response curves comparing PANC1 cell viability with SMARCA4 (vs. empty vector) expression, for (C) cisplatin, (D) oxaliplatin, (E) irinotecan, (F) 5-fluoruracil, (G) gemcitabine, and (H) paclitaxel. IC50 values indicated.